Exposure to antidepressants during pregnancy-prevalences and outcomes

Danish Medical Journal

Volumn 61, Issue 9, 2014, Pages

  Jimenez Solem, Espen ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ABNORMALITIES, DRUG-INDUCED; ADULT; ADVERSE EFFECTS; COHORT ANALYSIS; DENMARK; DRUG UTILIZATION; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; INFANT; INFANT MORTALITY; NEWBORN; PERINATAL DEATH; PREGNANCY; REGISTER; RISK FACTOR; STATISTICS AND NUMERICAL DATA; STILLBIRTH; TRENDS;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COHORT STUDIES; DENMARK; DRUG UTILIZATION; FEMALE; HUMANS; INFANT; INFANT MORTALITY; INFANT, NEWBORN; MATERNAL EXPOSURE; PERINATAL DEATH; PREGNANCY; REGISTRIES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; STILLBIRTH;

EID: 84906877018     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Andersen NL, Torp-Pedersen C, Poulsen HE. (2013) Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort study. PLoS ONE 8(4): e63034. doi:10.1371 /journal.pone.0063034
2. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Jensen JK, Afzal S, Gislason GH, Torp-Pedersen C, Poulsen HE. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2012;2:e001148. doi:10.1136
3. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Lander AR, Afzal S, Torp-Pedersen C, Poulsen HE. SSRI Use During Pregnancy and Risk of Stillbirth and Neona-tal Mortality. Am J Psychiatry. 2013 Jan 30. doi: 10.1176/appi.ajp. 2012.11081251
4. Grigoriadis S, Robinson GE. Gender issues in depression. Ann Clin Psychiatry 2007;19(4):247-255.
5. Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder - Results from the National Comorbidity Survey Replication (NCS-R). Jama-Journal of the American Medical Association 2003;289(23):3095-3105.
6. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004;103(4):698-709.
7. Chatillon O, Even C. Antepartum depression: Prevalence, diagnosis and treatment.]. Encephale 2010;36(6):443-451.
8. Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004;49(11):726-735.
9. Talati A, Wickramaratne PJ, Pilowsky DJ et al. Remission of maternal depression and child symptoms among single mothers: a STAR*D-Child report. Soc Psychiatry Psychiatr Epidemiol 2007;42(12):962-971.
10. Weissman MM, Wickramaratne P, Nomura Y, Warner V, Pilowsky D, Verdeli H. Offspring of depressed parents: 20 years later. Am J Psychiatry 2006;163(6):1001-1008.
11. Chung TKH, Lau TK, Yip ASK, Chiu HFK, Lee DTS. Antepartum Depressive Symptomatology Is Associated With Adverse Obstetric and Neonatal Outcomes. Psychosom Med 2001;63(5):830-834.
12. Beck CT, Records K, Rice M. Further development of the Postpartum Depression Predictors Inventory-Revised. J Obstet Gynecol Neonatal Nurs 2006;35(6):735-745.
13. Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006;62(10):863-870.
14. Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007;196(6):544-545.
15. Andrade SE, Raebel MA, Brown J et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008;198(2):194-195.
16. Alwan S, Reefhuis J, Rasmussen SA, Friedman JM, Prevention Study TNBD. Patterns of Antidepressant Medication Use Among Pregnant Women in a United States Population. J Clin Pharmacol 2010; 0091270010373928.
17. Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 2008;65(4):600-606.
18. Wichman CL, Fothergill A, Moore KM, Lang TR, Heise RH, Jr., Watson WJ. Recent trends in selective serotonin reuptake inhibitor use in pregnancy. J Clin Psychopharmacol 2008;28(6):714-716.
19. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356(26):2684-2692.
20. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356(26):2675-2683.
21. Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011;118(1):111-120.
22. Bakker MK, Kerstjens-Frederikse WS, Buys CH, de Walle HE, de Jong-van den Berg LT. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010;88(2):94-100.
23. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007;80(1):18-27.
24. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16(10):1075-1085.
25. Diav-Citrin O, Shechtman S, Weinbaum D et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008;66(5):695-705.
26. Kallen BA, Otterblad OP. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007;79(4):301-308.
27. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.
28. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;1-11.
29. Wichman CL, Moore KM, Lang TR, Sauver JLS, Heise RH, Watson WJ. Congenital Heart Disease Associated With Selective Serotonin Reuptake Inhibitor Use During Pregnancy. Mayo Clinic Proceedings 2009;84(1):23-27.
30. Wogelius P, Norgaard M, Gislum M et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006;17(6):701-704.
31. Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88(3):159-170.
32. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005;106(6):1289-1296.
33. Kulin NA, Pastuszak A, Sage SR et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998;279(8):609-610.
34. Ramos E, St-Andre M, Rey E, Oraichi D, Berard A. Duration of antidepressant use during pregnancy and risk of major congenital malformations. The British Journal of Psychiatry 2008;192(5):344-350.
35. Einarson A, Choi J, Einarson TR, Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 2009;54(4):242-246.
36. Davis RL, Rubanowice D, McPhillips H et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007;16(10):1086-1094.
37. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008;83(1):68-76.
38. Simon GE, Cunningham ML, Davis RL. Outcomes of Prenatal Antidepressant Exposure. Am J Psychiatry 2002;159(12):2055-2061.
39. Wen SW, Yang Q, Garner P et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006;194(4):961-966.
40. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;55(7):503-508.
41. Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reproductive Toxicology 2006;21(3):221-222.
42. Lennestal RM, Kallen BM. Delivery Outcome in Relation to Maternal Use of Some Recently Introduced Antidepressants. [Article]. Journal of Clinical Psychopharmacology 2007;27(6):607-613.
43. Kieler H, Artama M, Engeland A et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012;344:d8012.
44. Stephansson O, Kieler H, Haglund B et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013;309(1):48-54.
45. Udechuku A, Nguyen T, Hill R, Szego K. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry 2010;44(11):978-996.
46. Danish Medicines Agency. Risk of death or serious side effects in newborns following exposure to antidepressants (fluoxetine and other SSRIs). www.laegemiddelstyrelsen.dk. 1-3-2011. http://laegemiddelstyrelsen.dk/en/topics/side-effects-and-trials/side-effects/news/risk-of-death-or-serious-side-effects-in--ther-ssris. (accessed Apr 2013).
47. Danish Medicines Agency. Data on deaths or serious side effects in newborns from use of antidepressants (SSRIs). www.laegemiddelstyrelsen.dk. 14-3-2011. http://laegemiddelstyrelsen.dk/en/topics/side-effects-and-trials/side-effects/news/data-on-deaths-or-serious-side-effects-i--ants-ssris. (accessed Apr 2013).
48. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001;90(3):288-291.
49. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006;53(4):441-449.
50. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011;39(7 Suppl):22-25.
51. Statistics Denmark (2008) Containing detailed statistical information on the Danish Society. http://www.dst.dk/en (accessed Apr 2013)
52. Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan Med Bull 1998;45(3):320-323.
53. Blenstrup LT, Knudsen LB. Danish registers on aspects of reproduction. Scand J Public Health 2011;39(7 Suppl):79-82.
54. Knudsen LB. [Information on parity in the medical registry of births of the National Board of Health. Validation with the help of a new fertility database in Danish Statistics]. Ugeskr Laeger 1993;155(33):2525-2529.
55. Knudsen LB. The Danish Fertility Database. Dan Med Bull 1998;45(2):221-225.
56. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46(3):263-268.
57. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011;39(7 Suppl):38-41.
58. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997;44(4):445-448.
59. Madsen HK, Hallas J. [Danish drug consumption trends]. Ugeskr Laeger 2009;171(10):775-777.
60. Statens Serum Institut. MEDSTAT.DK. http://medstat.dk/en. 2013. (accessed Apr 2013)
61. Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007;196(6):544-545.
62. Petersen I, Gilbert RE, Evans SJ, Man SL, Nazareth I. Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. J Clin Psychiatry 2011.
63. FDA (2009) FDA Advising of Risk of Birth Defects with Paxil. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108527.htm (accessed Apr 2013).
64. Schatzberg AF. New indications for antidepressants. J Clin Psychiatry 2000;61 Suppl 11:9-17.
65. Goodman JH. Women's attitudes, preferences, and perceived barriers to treatment for perinatal depression. Birth 2009;36(1):60-69.
66. De las CC, Sanz E. Do therapeutic indications of antidepressants change from one year to another? Pharmacoepidemiol Drug Saf 2004;13(5):309-314.
67. Munk-Olsen T GCLTM. Prevalence of antidepressant use and contacts with psychiatrists and psychologists in pregnant and postpartum women. Acta Psychiatr Scand 2012.
68. Ramos E, Oraichi D, Rey E, Blais L, Berard A. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG 2007;114(9):1055-1064.
69. Reefhuis J, Rasmussen SA, Friedman JM. Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354(20):2188-2190.
70. Danish Society of Obstetrics and Gynaecology. [Behandling med serotoningenoptagshæmmere i graviditeten og under amningen] DANISH. urlwww.dsog.dk. (accessed Apr 2013)
71. Cohen LS, Nonacs RM, Bailey JW et al. Relapse of depression during pregnancy following antidepressant discontinuation: a preliminary prospective study. Arch Womens Ment Health 2004;7(4):217-221.
72. Cohen LS, Altshuler LL, Harlow BL et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295(5):499-507.
73. O'Brien L, Laporte A, Koren G. Estimating the economic costs of antidepressant discontinuation during pregnancy. Can J Psychiatry 2009;54(6):399-408.
74. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001;26(1):44-48.
75. Walfisch A. Maternal depression and perception of teratogenicity. J Popul Ther Clin Pharmacol 2012;19(3):e376-e379.
76. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Norgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010;2:29-36.
77. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997;89(5 Pt 1):713-718.
78. Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G. Citalopram use in pregnancy: Prospective comparative evaluation of pregnancy and fetal outcome. American Journal of Obstetrics and Gynecology 2005;193(6):2004-2009.
79. Richelson E. Synaptic effects of antidepressants. J Clin Psychopharmacol 1996;16(3 Suppl 2):1S-7S.
80. Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007;164(8):1206-1213.
81. Wisner KL, Sit DK, Hanusa BH et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009;166(5):557-566.
82. Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008;17(8):801-806.
83. de Jong van den Berg LT, Feenstra N, Sorensen HT, Cornel MC. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. Europen Medicine and Pregnancy Group. Teratology 1999;60(1):33-36.
84. Olesen C, Sondergaard C, Thrane N, Nielsen GL, de Jong-van den Berg, Olsen J. Do pregnant women report use of dispensed medications? Epidemiology 2001;12(5):497-501.
85. Paganini-Hill A, Ross RK. Reliability of recall of drug usage and other health-related information. Am J Epidemiol 1982;116(1):114-122.
86. Tilley BC, Barnes AB, Bergstralh E et al. A comparison of pregnancy history recall and medical records.Implications for retrospective studies. Am J Epidemiol 1985;121(2):269-281.
87. Van den Brandt PA, Petri H, Dorant E, Goldbohm RA, Van de Crommert S. Comparison of questionnaire information and pharmacy data on drug use. Pharm Weekbl Sci 1991;13(2):91-96.
88. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995;142(10):1103-1112.
89. Bar-Oz B, Einarson T, Einarson A et al. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther 2007;29(5):918-926.
90. Sorensen HT, Hansen I, Ejlersen E, Sabroe S, Hamburger H. Identification of patients treated with strong analgesics: an assessment of two Danish information systems with respect to epidemiological research. J Med Syst 1996;20(1):57-65.
91. Knudsen LB. The Danish Fertility Database. Dan Med Bull 1998;45(2):221-225.
92. Larsen H, Nielsen GL, Bendsen J, Flint C, Olsen J, Sorensen HT. Predictive value and completeness of the registration of congenital abnormalities in three Danish population-based registries. Scand J Public Health 2003;31(1):12-16.
93. Gregg NM. Congenital cataract following German measles in the mother. 1941. Aust N Z J Ophthalmol 1991;19(4):267-276.
94. McBride WG. Thalidomide and congenital abnormalities. The Lancet 1961;(ii):1358.
95. Koren G. Depression in pregnancy: time to stop terrifying pregnant women. J Popul Ther Clin Pharmacol 2012;19(3):e369-e370.
96. Koren G, Nordeng HM. Selective serotonin reuptake inhibitors and malformations: case closed? Semin Fetal Neonatal Med 2013;18(1):19-22.